Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction price of 1743.15 pence per share.
Material Changes
The filing reports increases in the personal shareholdings of several executives following the re-investment of dividends paid on July 11, 2013. The transactions occurred on July 16, 2013. No material changes to the company's financial position or operations are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Directors and senior managers increased their holdings via dividend re-investment.
- Transaction Date: July 16, 2013.
- Share Price: 1743.15 pence per share.
- Key Participants: Sir Andrew Witty, Dr M M Slaoui, Mr S M Bicknell, Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mr C Weber.
- Notification Date: The company was advised of these transactions on July 18, 2013.